News | February 01, 2024
Zydus Lifesciences launches Rexigo
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
Gabapentin is indicated for the management of Postherpetic Neuraligia
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
Pimavanserin is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson disease psychosis
This PAI-cum-GMP USFDA inspection was conducted from December 14 to December 22, 2023
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
Lacosamide is indicated to treat partial-onset seizures
Darunavir is a protease inhibitor antiviral medicine that prevents Human Immunodeficiency Virus (HIV-1) from multiplying in the body
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
Subscribe To Our Newsletter & Stay Updated
